Marksans Pharma Ltd

Marksans Pharma has completed the acquisition of 100% share capital of QliniQ B.V. based in the Netherlands.

Marksans Pharma has received affirmation in credit ratings for bank facilities at IND AA-/ IND A1+ while outlook has been revised to 'Positive' from 'Stable'.

Marksans Pharma announced that it has entered into a definitive agreement to acquire 100% of the share capital of QliniQ B.V., a profitable Netherlands-based pharmaceutical company with established front-end sales, marketing, and distribution capabilities across the Dutch healthcare market. The acquisition marks a strategic step in expanding Marksans' presence across regulated European markets and strengthening its forward-integration strategy through direct, owned market-access capabilities in the European Union. QliniQ operates a differentiated portfolio of niche pharmaceuticals and medical devices, with established positions across women's health, dermatology, respiratory care, and other specialty categories. The company has developed long-standing relationships across wholesalers, pharmacies, hospitals and insurer led tender channels in the Netherlands, supporting sustainable market access and growth. For the financial year ended 31 December 2025, QliniQ reported revenue of '9.35 million and net profit of '1.01 million. The company has delivered strong profitable growth, with revenue increasing at a CAGR of approximately 41% between FY2023 and FY2025, while maintaining a debt-free balance sheet.

Net profit of Marksans Pharma rose 63.59% to Rs 148.13 crore in the quarter ended March 2026 as against Rs 90.55 crore during the previous quarter ended March 2025. Sales rose 20.84% to Rs 856.11 crore in the quarter ended March 2026 as against Rs 708.46 crore during the previous quarter ended March 2025. For the full year,net profit rose 9.81% to Rs 417.90 crore in the year ended March 2026 as against Rs 380.58 crore during the previous year ended March 2025. Sales rose 12.51% to Rs 2950.94 crore in the year ended March 2026 as against Rs 2622.85 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales856.11708.46 21 2950.942622.85 13 OPM %22.8317.92 -20.3620.31 - PBDT224.29138.84 62 659.19587.35 12 PBT200.00116.09 72 560.56503.97 11 NP148.1390.55 64 417.90380.58 10 Powered by Capital Market - Live

Marksans Pharma announced that the Board of Directors of the Company at its meeting held on 26 May 2026, inter alia, have recommended the final dividend of Rs 0.9 per equity Share (i.e. 90%) , subject to the approval of the shareholders.

The key equity barometers traded with modest losses in the mid-afternoon trade as geopolitical concerns resurfaced following fresh US strikes on Iran dampened hopes of a peace deal. Investors turned cautious after the sharp rally witnessed in the previous two sessions. Investors remained watchful of crude oil and gold prices. The Nifty traded below the 24,000 level. . At 14:25 ST, the barometer index, the S&P BSE Sensex slipped 425.31 points or 0.55% to 76,064.72. The Nifty 50 index fell 97.80 points or 0.40% to 23,933.10. The broader market outperformed the frontline indices. The BSE 150 MidCap Index added 0.18% and the BSE 250 SmallCap Index jumped 0.22%. The market breadth was almost even. On the BSE, 2,062 shares rose and 2,054 shares fell. A total of 206 shares were unchanged. The NSE's India VIX, a gauge of the market's expectation of volatility over the near term, fell 3.05% to 16.19. Buzzing Index: The Nifty PSU Bank shares declined 0.65% to 8,184.20. The index rallied 4.64% in the past five trading sessions. Bank of Maharashtra (down 1.37%), Bank of India (down 1.29%), Union Bank of India (down 1.01%), Indian Bank (down 0.93%), Indian Overseas Bank (down 0.83%), Bank of Baroda (down 0.77%), State Bank of India (down 0.63%), Central Bank of India (down 0.58%), Punjab National Bank (down 0.56%) and Canara Bank (down 0.55%) declined. Numbers to Tracks: The yield on India's 10-year benchmark federal paper advanced 0.10% to 7.032 compared with previous session close of 7.025. In the foreign exchange market, the rupee edged lower against the dollar. The partially convertible rupee was hovering at 95.5975 compared with its close of 95.2600 during the previous trading session. MCX Gold futures for 5 June 2026 settlement fell 0.84% to Rs 157,750. The US Dollar Index (DXY), which tracks the greenback's value against a basket of currencies, was down 0.17% to 99.08. The United States 10-year bond yield declined 1.36% to 4.511. In the commodities market, Brent crude for July 2026 settlement dropped $3.98 or 3.84% to $99.56 a barrel. Stocks in Spotlight: Marksans Pharma surged 12.69% after the company reported strong growth in quarterly earnings. On a consolidated basis, the company reported a net profit of Rs 148.12 crore in Q4 FY26, up 63.60% YoY and 30.85% QoQ. Revenue from operations rose 20.84% YoY to Rs 856.11 crore in Q4 FY26, while increasing 13.48% QoQ. Container Corporation of India (CONCOR) fell 7.41% after the company reported a 12.38% decline in consolidated net profit to Rs 262.65 crore in Q4 FY26, compared with Rs 299.79 crore posted in the corresponding quarter last year. Revenue from operations slipped 1.1% year-on-year to Rs 2,263.30 crore in the quarter ended 31 March 2026.Powered by Capital Market - Live

On a consolidated basis, the company reported a net profit of Rs 148.12 crore in Q4 FY26, up 63.60% YoY and 30.85% QoQ. Revenue from operations rose 20.84% YoY to Rs 856.11 crore in Q4 FY26, while increasing 13.48% QoQ. Gross profit stood at Rs 465.5 crore in Q4 FY26, up 21.5% YoY and 6.2% QoQ. Gross margin improved to 54.4% from 54.1% in Q4 FY25, supported by favourable product mix, softening raw material prices and forex tailwinds. Profit before tax stood at Rs 199.99 crore in Q4 FY26, up 72.27% YoY and 32.78% QoQ. EBITDA stood at Rs 195.4 crore in Q4 FY26, up 54% YoY and 21.6% QoQ. EBITDA margin expanded sharply to 22.8% from 17.9% in the year-ago period and 21.3% in Q3 FY26, aided by operating leverage and tight cost controls. On the cost front, raw material costs increased 40.89% YoY to Rs 264.97 crore, while employee expenses rose 9.81% YoY to Rs 106.75 crore. Interest costs climbed 83.97% YoY to Rs 6.31 crore, while depreciation expenses increased 6.77% YoY to Rs 24.28 crore. The company said quarterly growth was driven by new launches in Australia and the UK, while price erosion in the UK market stabilized during the quarter. Marksans Pharma also launched its first Rx branded products in Australia during Q4 FY26. Management added that Australia and New Zealand revenues grew 61% YoY, while the US and North America business increased 24% YoY, supported by traction from new product launches and expansion across OTC store brands. The company noted that gross margin expansion was supported by softening raw material prices, favourable product mix and forex gains. However, sequential gross margin moderated due to rising input costs linked to ongoing geopolitical tensions. For the full year FY26, net profit rose 9.81% YoY to Rs 417.9 crore, while revenue increased 12.51% YoY to Rs 2,950.93 crore. PBT for FY26 rose 11.23% YoY to Rs 560.55 crore. EBITDA for FY26 stood at Rs 600.8 crore, up 12.8% YoY, while EBITDA margin improved marginally to 20.4% from 20.3% in FY25. Net cash flow from operating activities improved sharply to Rs 458.12 crore in FY26 from Rs 206.66 crore in FY25. The company reported a cash balance of Rs 990 crore as of 31 March 2026. The board recommended a final dividend of Rs 0.90 per equity share of face value Re 1 each for FY26. Marksans Pharma is engaged in the research, manufacturing and marketing of pharmaceutical formulations across regulated and emerging markets, with a strong presence in OTC and prescription products. Powered by Capital Market - Live

Marksans Pharma has granted 3 lakh stock options to certain eligible employees of the Company and its subsidiaries under Marksans Employees Stock Option Scheme 2024.

Marksans Pharma will hold a meeting of the Board of Directors of the Company on 26 May 2026.

The approved product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Tessalon Capsules, 100 mg and 200 mg, marketed by Pfizer Inc. Benzonatate is a non-narcotic antitussive that works by numbing stretch receptors in the respiratory tract, thereby suppressing the cough reflex. It is commonly used for the symptomatic relief of persistent cough associated with conditions such as bronchitis, pneumonia, and other respiratory infections. Marksans Pharma is primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulations. The company's consolidated net profit increased 8.26% year-on-year to Rs 113.20 crore, despite a 10.64% jump in revenue from operations to Rs 754.42 crore in Q3 FY26 compared with Q3 FY25.